| Identification | Back Directory | [Name]
JNJ-64619178 | [CAS]
2086772-26-9 | [Synonyms]
CS-2829
JNJ-64619178
JNJ 64619178;JNJ64619178
1,2-Cyclopentanediol, 3-[2-(2-amino-3-bromo-7-quinolinyl)ethyl]-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-, (1S,2R,3S,5R)- | [Molecular Formula]
C22H23BrN6O2 | [MDL Number]
MFCD31813596 | [MOL File]
2086772-26-9.mol | [Molecular Weight]
483.36 |
| Chemical Properties | Back Directory | [Boiling point ]
636.2±50.0 °C(Predicted) | [density ]
1.79±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:111.0(Max Conc. mg/mL);229.64(Max Conc. mM) | [form ]
A solid | [pka]
13.37±0.70(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
Onametostat (JNJ-64619178) is a selective, orally active and pseudo-irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC50 of 0.14 nM. Onametostat has potent activity in lung cancer[1][2]. | [in vivo]
Oral administration of Onametostat results in efficient inhibition of dimethylation of SMD1/3 proteins, components of the splicing machinery and direct substrates of the methylosome, in several non-small cell lung cancer and small cell lung cancer? cancer mouse xenograft models[1]. | [IC 50]
PRMT5 | [References]
[1] Tongfei Wu, et al. Abstract 4859: JNJ-64619178, a selective and pseudo-irreversible PRMT5 inhibitor with potent in vitro and in vivo activity, demonstrated in several lung cancer models.
[2] Tao H, et al. Discovery of Novel PRMT5 Inhibitors by Virtual Screening and Biological Evaluations. Chem Pharm Bull (Tokyo). 2019;67(4):382-388. DOI:10.1248/cpb.c18-00980 |
|
|